'I Don't Like Uncertainty, I Like to Know': How and why uveal melanoma patients consent to life expectancy prognostication

被引:1
|
作者
Brown, Stephen L. [1 ]
Fisher, Peter L. [2 ]
Morgan, Andrew [2 ]
Davies, Cari [2 ]
Olabi, Yasmin [2 ]
Hope-Stone, Laura [1 ,2 ,3 ]
Heimann, Heinrich [2 ,3 ]
Hussain, Rumana [2 ,3 ]
Cherry, Mary Gemma [1 ]
机构
[1] Univ Plymouth, Sch Psychol, Plymouth PL4 8AA, Devon, England
[2] Univ Liverpool, Dept Psychol Sci, Liverpool, Merseyside, England
[3] Liverpool Univ Hosp NHS Fdn Trust, Liverpool Ocular Oncol Ctr, Liverpool, Merseyside, England
关键词
medical ethics; patient decision-making; prognostication; qualitative; uveal melanoma; QUALITY-OF-LIFE; DECISION-MAKING; INFORMED-CONSENT; CANCER; EXPERIENCE; DISEASE; ASSOCIATIONS; VALIDATION; PREDICTION; SURVIVAL;
D O I
10.1111/hex.13490
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Technological advances have led to cancer prognostication that is increasingly accurate but often unalterable. However, a reliable prognosis of limited life expectancy can cause psychological distress. People should carefully consider offers of prognostication, but little is known about how and why they decide on prognostication. Using uveal melanoma (UM) patients, we aimed to identify (i) how and why do people with UM decide to accept prognostication and (ii) alignment and divergence of their decision-making from conceptualizations of a 'well-considered' decision. Methods UM provides a paradigm to elucidate clinical and ethical perspectives on prognostication, because prognostication is reliable but prognoses are largely nonameliorable. We used qualitative methods to examine how and why 20 UM people with UM chose prognostication. We compared findings to a template of 'well-considered' decision-making, where 'well-considered' decisions involve consideration of all likely outcomes. Results Participants wanted prognostication to reduce future worry about uncertain life expectancy. They spontaneously spoke of hoping for a good prognosis when making their decisions, but largely did not consider the 50% possibility of a poor prognosis. When pressed, they argued that a poor outcome at least brings certainty. Conclusions While respecting decisions as valid expressions of participants' wishes, we are concerned that they did not explicitly consider the realistic possibility of a poor outcome and how this would affect them. Thus, it is difficult to see their decisions as 'well-considered'. We propose that nondirective preference exploration techniques could help people to consider the possibility of a poor outcome. Patient or Public Contribution This paper is a direct response to a patient-identified and defined problem that arose in therapeutic and conversational discourse. The research was informed by the responses of patient participants, as we used the material from interviews to dynamically shape the interview guide. Thus, participants' ideas drove the analysis and shaped the interviews to come.
引用
收藏
页码:1498 / 1507
页数:10
相关论文
共 43 条
  • [41] "I Don't Feel Like the Odd One": Utilizing Content Analysis to Compare the Effects of Social Media Use on Well-Being Among Sexual Minority and Nonminority US Young Adults
    Escobar-Viera, Cesar
    Shensa, Ariel
    Hamm, Megan
    Melcher, Eleanna M.
    Rzewnicki, Daniel, I
    Egan, James E.
    Sidani, Jaime E.
    Primack, Brian A.
    AMERICAN JOURNAL OF HEALTH PROMOTION, 2020, 34 (03) : 285 - 293
  • [42] Insulin-like growth factor I receptor density on CD4+T-lymphocytes from active early steroid- and DMARD-na⟨ve rheumatoid arthritis patients is up-regulated and not influenced by 1 year of clinically effective treatment
    Laurberg, Trine Bay
    Ellingsen, Torkell
    Thorsen, Jonas
    Moller, Bjarne Kuno
    Hansen, Ib
    Tarp, Ulrik
    Hetland, Merete Lund
    Horslev-Petersen, Kim
    Flyvbjerg, Allan
    Frystyk, Jan
    Stengaard-Pedersen, Kristian
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (02) : 501 - 504
  • [43] Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
    Minocha, Mukul
    Thompson, Corbin G.
    Murphy, Alexis
    Zhou, Yanchen
    Brandl, Christian
    Parkes, Amanda
    Chen, Xi
    Yu, Brian
    Martinez, Pablo
    Houk, Brett E.
    CLINICAL PHARMACOKINETICS, 2024, 63 (12) : 1757 - 1768